Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | SNCA | P37840 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27700693 | 0.88 | DHODH (0.78) | DHODHPTGS1PDE4ASNCAPDE3A | |
| SCHEMBL572130 | 0.84 | PTGS1 (0.63) | DHODHPTGS1PDE4ASNCAPDE3A | |
| SCHEMBL571987 | 0.84 | PTGS1 (0.63) | DHODHPTGS1PDE4ASNCAPDE3A | |
| SCHEMBL17296075 | 0.84 | PTGS1 (0.63) | DHODHPTGS1PDE4ASNCAPDE3A | |
| SCHEMBL572073 | 0.84 | PTGS1 (0.63) | DHODHPTGS1PDE4ASNCAPDE3A | |
| SCHEMBL12473794 | 0.84 | PTGS1 (0.63) | DHODHPTGS1PDE4ASNCAPDE3A | |
| SCHEMBL571584 | 0.84 | PTGS1 (0.63) | DHODHPTGS1PDE4ASNCAPDE3A | |
| SCHEMBL571963 | 0.84 | PTGS1 (0.63) | DHODHPTGS1PDE4ASNCAPDE3A | |
| SCHEMBL571611 | 0.84 | PTGS1 (0.63) | DHODHPTGS1PDE4ASNCAPDE3A | |
| SCHEMBL31462882 | 0.82 | PTGS1 (0.49) | DHODHPTGS1PDE4ASNCAPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030170865-A1 | Novel polypeptide of protein p140 and DNAs encoding it | ONO PHARMACEUTICAL CO., LTD. | 2003-09-11 | — | — | US | disclosed |
| EP-0659883-B1 | Protein p140 and DNA encoding it | ONO PHARMACEUTICAL CO (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-6432913-B1 | ANTIDIABETIC AGENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| US-6303320-B1 | SCREENING FOR MODULATOR OF GLUCOSE USE; ADMINISTER MODULATOR TO CELLS IN VITRO, CULTURE CELLS, COMPARE PHOSPHORYLATED PROTEIN WITH GLUCOSE USE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-10-16 | — | — | US | disclosed |
| US-5804411-A | KEY PROTEIN IN THE SIGNAL TRANSMISSION OF INSULIN; USEFUL IN THE PREVENTION AND/OR TREATMENT OF DIABETES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1998-09-08 | — | — | US | disclosed |
| US-5506205-A | TREATMENT OF DIABETES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| EP-0659883-A2 | Protein p140 and DNA encoding it | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030170865-A1 | Novel polypeptide of protein p140 and DNAs encoding it | IAPP, FAM20C, GID4 | DHODH 4219/4885PTGS1 4724/4885PDE4A 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.